Title:
METHODS OF USING ITRACONAZOLE DRY POWDERS
Document Type and Number:
WIPO Patent Application WO/2024/049982
Kind Code:
A3
Abstract:
The present disclosure relates to a method of treating a disease or disorder in a subject for whom oral itraconazole is contraindicated, comprising administering to the respiratory tract of the subject a respirable dry powder comprising itraconazole. The present disclosure also relates to methods of co-administering itraconazole with a second therapeutic agent to a subject in need thereof, wherein the itraconazole is administered as a respirable dry powder to the respiratory tract of the subject, and wherein the second therapeutic agent is a substrate, inducer, and/or inhibitor of an enzyme or receptor that is inhibited by, or metabolizes, itraconazole.
Inventors:
CURRAN AIDAN (US)
Application Number:
PCT/US2023/031675
Publication Date:
May 02, 2024
Filing Date:
August 31, 2023
Export Citation:
Assignee:
PULMATRIX OPERATING CO INC (US)
International Classes:
A61K31/496; A61K9/00; A61K31/5517; A61K45/06; A61P11/00; A61P11/06; A61P11/14; A61P31/10
Domestic Patent References:
| WO2019204583A1 | 2019-10-24 |
Foreign References:
| US20110190245A1 | 2011-08-04 | |||
| US20190167579A1 | 2019-06-06 |
Other References:
DAVID L HAVA ET AL: "A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, vol. 86, no. 4, 16 January 2020 (2020-01-16), pages 723 - 733, XP071603579, ISSN: 0306-5251, DOI: 10.1111/BCP.14166
Attorney, Agent or Firm:
CONNARN, Kristin, A. (US)
Download PDF: